These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 19757300)

  • 1. Limited prognostic value of the International Prognostic Score in advanced stage human immunodeficiency virus infection-related Hodgkin lymphoma treated with the doxorubicin, bleomycin, vinblastine, and dacarbazine regimen.
    Xicoy B; Ribera JM; Miralles P; Berenguer J; Rubio R; Mahillo B; Valencia ME; Abella E; López-Guillermo A; Sureda A; Morgades M; Navarro JT; Esteban H
    Leuk Lymphoma; 2009 Oct; 50(10):1718-20. PubMed ID: 19757300
    [No Abstract]   [Full Text] [Related]  

  • 2. Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: a multi-institutional retrospective study.
    Castillo JJ; Bower M; Brühlmann J; Novak U; Furrer H; Tanaka PY; Besson C; Montoto S; Cwynarski K; Abramson JS; Dalia S; Bibas M; Connors JM; Furman M; Nguyen ML; Cooley TP; Beltran BE; Collins JA; Vose JM; Xicoy B; Ribera JM;
    Cancer; 2015 Feb; 121(3):423-31. PubMed ID: 25251326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphoma.
    Xicoy B; Ribera JM; Miralles P; Berenguer J; Rubio R; Mahillo B; Valencia ME; Abella E; López-Guillermo A; Sureda A; Morgades M; Navarro JT; Esteban H; ;
    Haematologica; 2007 Feb; 92(2):191-8. PubMed ID: 17296568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era.
    Montoto S; Shaw K; Okosun J; Gandhi S; Fields P; Wilson A; Shanyinde M; Cwynarski K; Marcus R; de Vos J; Young AM; Tenant-Flowers M; Orkin C; Johnson M; Chilton D; Gribben JG; Bower M
    J Clin Oncol; 2012 Nov; 30(33):4111-6. PubMed ID: 23045581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study.
    Hentrich M; Berger M; Wyen C; Siehl J; Rockstroh JK; Müller M; Fätkenheuer G; Seidel E; Nickelsen M; Wolf T; Rieke A; Schürmann D; Schmidmaier R; Planker M; Alt J; Mosthaf F; Engert A; Arasteh K; Hoffmann C
    J Clin Oncol; 2012 Nov; 30(33):4117-23. PubMed ID: 23045592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hodgkin lymphoma among patients infected with HIV in post-HAART era.
    Tanaka PY; Pessoa VP; Pracchia LF; Buccheri V; Chamone DA; Calore EE
    Clin Lymphoma Myeloma; 2007 Mar; 7(5):364-8. PubMed ID: 17562247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term follow up of patients with human immunodeficiency virus infection and advanced stage Hodgkin's lymphoma treated with doxorubicin, bleomycin, vinblastine and dacarbazine.
    Xicoy B; Miralles P; Morgades M; Rubio R; Valencia ME; Ribera JM
    Haematologica; 2013 Aug; 98(8):e85-6. PubMed ID: 23716563
    [No Abstract]   [Full Text] [Related]  

  • 8. Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection.
    Spina M; Gabarre J; Rossi G; Fasan M; Schiantarelli C; Nigra E; Mena M; Antinori A; Ammassari A; Talamini R; Vaccher E; di Gennaro G; Tirelli U
    Blood; 2002 Sep; 100(6):1984-8. PubMed ID: 12200356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hodgkin's disease in HIV-infected patients: report of eight cases usefully treated with doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) plus granulocyte colony- stimulating factor.
    Gastaldi R; Martino P; Gentile G; Picardi V; De Propris MS; Pirillo MF; De Vellis A; Mandelli F
    Ann Oncol; 2002 Jul; 13(7):1158-60. PubMed ID: 12176798
    [No Abstract]   [Full Text] [Related]  

  • 10. Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era.
    Jalali A; Ha FJ; Chong G; Grigg A; Mckendrick J; Schwarer AP; Doig R; Hamid A; Hawkes EA
    Ann Hematol; 2016 Apr; 95(5):809-16. PubMed ID: 26878861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence, predictors and significance of severe toxicity in patients with human immunodeficiency virus-associated Hodgkin lymphoma.
    Ezzat HM; Cheung MC; Hicks LK; Boro J; Montaner JS; Lima VD; Harris M; Leitch HA
    Leuk Lymphoma; 2012 Dec; 53(12):2390-6. PubMed ID: 22642935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ABVD or BEACOPP
    Fermé C; Thomas J; Brice P; Casasnovas O; Vranovsky A; Bologna S; Lugtenburg PJ; Bouabdallah R; Carde P; Sebban C; Eghbali H; Salles G; van Imhoff GW; Thyss A; Noordijk EM; Reman O; Lybeert MLM; Janvier M; Spina M; Audhuy B; Raemaekers JMM; Delarue R; Anglaret B; de Weerdt O; Marjanovic Z; Tersteeg RJHA; de Jong D; Brière J; Henry-Amar M; ;
    Eur J Cancer; 2017 Aug; 81():45-55. PubMed ID: 28601705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stanford V regimen and concomitant highly active antiretroviral therapy is feasible and active in patients with Hodgkin's disease and HIV infection.
    Spina M; Gabarre J; Fasan M; Vaccher E; Tirelli U
    AIDS; 2000 Jul; 14(10):1457-8. PubMed ID: 10930165
    [No Abstract]   [Full Text] [Related]  

  • 14. Does Radiation Have a Role in Advanced Stage Hodgkin's or Non-Hodgkin Lymphoma?
    Specht L
    Curr Treat Options Oncol; 2016 Jan; 17(1):4. PubMed ID: 26739151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current status of the treatment of HIV-associated lymphoma.
    Kaplan LD
    Clin Adv Hematol Oncol; 2004 Jan; 2(1):28-9. PubMed ID: 16163156
    [No Abstract]   [Full Text] [Related]  

  • 16. Increased relapse rates in early stage hodgkin lymphoma (HL) patients without radiotherapy: the German Society of Radiooncology (DEGRO) advises to treat all early stage HL patients with radiotherapy.
    Körholz D; Mauz-Körholz C; Vordermark D; Kluge R; Dieckmann K
    Klin Padiatr; 2014 Nov; 226(6-7):307-8. PubMed ID: 25431863
    [No Abstract]   [Full Text] [Related]  

  • 17. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial.
    Behringer K; Goergen H; Hitz F; Zijlstra JM; Greil R; Markova J; Sasse S; Fuchs M; Topp MS; Soekler M; Mathas S; Meissner J; Wilhelm M; Koch P; Lindemann HW; Schalk E; Semrau R; Kriz J; Vieler T; Bentz M; Lange E; Mahlberg R; Hassler A; Vogelhuber M; Hahn D; Mezger J; Krause SW; Skoetz N; Böll B; von Tresckow B; Diehl V; Hallek M; Borchmann P; Stein H; Eich H; Engert A; ; ;
    Lancet; 2015 Apr; 385(9976):1418-27. PubMed ID: 25539730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Doxorubicin, bleomycin, vinblastine, and dacarbazine alone in treatment of favorable, limited-stage Hodgkin's lymphoma: do we really have robust data?
    Basaran G; Agaoglu F; Basaran M
    J Clin Oncol; 2010 Sep; 28(27):e485-6; author reply e487. PubMed ID: 20606082
    [No Abstract]   [Full Text] [Related]  

  • 19. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi.
    Gobbi PG; Levis A; Chisesi T; Broglia C; Vitolo U; Stelitano C; Pavone V; Cavanna L; Santini G; Merli F; Liberati M; Baldini L; Deliliers GL; Angelucci E; Bordonaro R; Federico M;
    J Clin Oncol; 2005 Dec; 23(36):9198-207. PubMed ID: 16172458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unusual manifestation of Hodgkin disease.
    Dunlap N; Parkhie S
    Am J Clin Oncol; 2006 Oct; 29(5):529-30. PubMed ID: 17023792
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.